Features | Partner Sites | Information | LinkXpress
Sign In
PZ HTL SA
GLOBETECH PUBLISHING LLC
GLOBETECH PUBLISHING LLC

New Drug Triggers Liver Regeneration After Surgery

By BiotechDaily International staff writers
Posted on 25 Aug 2014
Image: Liver cells regenerated in mice treated with a new drug (right) compared with a control group (center) after partial liver removal. Healthy liver cells are shown at left (Photo courtesy of Marshall et al, 2014, the Journal of Experimental Medicine).
Image: Liver cells regenerated in mice treated with a new drug (right) compared with a control group (center) after partial liver removal. Healthy liver cells are shown at left (Photo courtesy of Marshall et al, 2014, the Journal of Experimental Medicine).
Investigators have revealed that an innovative complement inhibitor decreases complement-mediated liver cell death, and actually stimulates postsurgery liver regrowth in mice.

Liver cancer often results in a loss of blood flow, and consequently, oxygen and nutrients to the liver tissue, resulting in deteriorating liver function. Although the diseased part of the liver can often be surgically removed, the sudden restoration of blood flow to the remaining liver tissue can trigger inflammation—a process called ischemia reperfusion injury (IRI). IRI occurs partly from the deposition of immune proteins called complement on the surface of liver cells, causing them to die and thereby impairing liver regeneration.

Complement inhibitors effectively suppress IRI, but the benefits of this approach come at a cost, because specific complement proteins are also required for liver tissue to regrow. According to scientists from the Medical University of South Carolina (MUSC; Charleston, USA), the novel inhibitor suppressed the deposition of complement proteins and promoted the division of new liver cells. Even after removal of as much as 90% of the liver, treatment increased survival from 0% in untreated animals to an impressive 70%. The study’s findings were published August 11, 2014, in the Journal of Experimental Medicine.

The selectivity of this unique complement inhibitor, and its unforeseen ability to enhance liver regeneration, suggests that it might represent a new treatment strategy for a range of liver injuries in humans, according to the researchers.

Related Links:

Medical University of South Carolina



BIOSIGMA S.R.L.
RANDOX LABORATORIES
SLAS - Society for Laboratory Automation and Screening
comments powered by Disqus

Channels

Drug Discovery

view channel

Omega 3 Found to Improve Behavior in Children with ADHD

Supplements of the fatty acids omega 3 and 6 can help children and adolescents who have a specific kind of have attention deficit hyperactivity disorder (ADHD). Moreover, these findings indicate that a customized cognitive training program can improve problem behavior in children with ADHD. Statistics show that 3%–6%... Read more

Biochemistry

view channel

Blocking Enzyme Switch Turns Off Tumor Growth in T-Cell Acute Lymphoblastic Leukemia

Researchers recently reported that blocking the action of an enzyme “switch” needed to activate tumor growth is emerging as a practical strategy for treating T-cell acute lymphoblastic leukemia. An estimated 25% of the 500 US adolescents and young adults diagnosed yearly with this aggressive disease fail to respond to... Read more

Lab Technologies

view channel
Image: On target: When researchers introduced nanobodies they made to cells engineered to express a tagged version of a protein in skeletal fibers known as tubulin (red), the nanobodies latched on. The cells above have recently divided (Photo courtesy of Rockefeller University).

Turning Antibodies into Precisely Tuned Nanobodies

New technology has the potential to create nanobodies making them much more accessible than antibodies for all sorts of research. Antibodies control the process of recognizing and zooming in on molecular... Read more

Business

view channel

Two Industry Partnerships Initiated to Fuel Neuroscience Research

Faster, more complex neural research is now attainable by combining technology from two research companies. Blackrock Microsystems, LLC (Salt Lake City, UT, USA), a developer of neuroscience research equipment, announced partnerships with two neuroscience research firms—PhenoSys, GmbH (Berlin, Germany) and NAN Instruments, Ltd.... Read more
 
Copyright © 2000-2014 Globetech Media. All rights reserved.